| Publikationstyp: | Beitrag in wissenschaftlicher Zeitschrift |
| Art der Begutachtung: | Peer review (Publikation) |
| Titel: | The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds? |
| Autor/-in: | Sandmann, Frank G. Mostardt, Sarah Lhachimi, Stefan K. Gerber-Grote, Andreas |
| DOI: | 10.1080/14737167.2018.1497976 |
| Erschienen in: | Expert Review of Pharmacoeconomics & Outcomes Research |
| Band(Heft): | 18 |
| Heft: | 5 |
| Seite(n): | 475 |
| Seiten bis: | 486 |
| Erscheinungsdatum: | 2018 |
| Verlag / Hrsg. Institution: | Taylor & Francis |
| ISSN: | 1473-7167 1744-8379 1744-8379 |
| Sprache: | Englisch |
| Schlagwörter: | Reference pricing; Cost effectiveness; Decision making; Economic evaluation; Health technology assessment; Benchmarking; Cost-Benefit Analysis; Drug Costs; Germany; Humans; Outcome Assessment (Health Care); Pharmaceutical Preparations; Technology Assessment, Biomedical; Economics; Quality-Adjusted Life Years; Medical |
| Fachgebiet (DDC): | 362.1041: Gesundheitsökonomie |
| Zusammenfassung: | The efficiency-frontier approach (EFA) to health economic evaluation aims to benchmark the relative efficiency of new drugs with the incremental cost-effectiveness ratios (ICERs) of non-dominated comparators. By explicitly considering any differences in health outcomes and costs, it enhances the internal reference pricing (IRP) policy that was officially endorsed by Germany as the first country worldwide in 1989. However, the EFA has been repeatedly criticized since its official endorsement in 2009. Areas covered: This perspective aims to stimulate the debate by discussing whether the main objections to the EFA are technically valid, irrespective of national contextual factors in Germany with reservations towards using cost-per-quality-adjusted life year (QALY) thresholds. Moreover, we comparatively assessed whether the objections are truly unique to the EFA or apply equally to IRP and cost-effectiveness thresholds. Expert commentary: The plethora of objections to the EFA (n = 20) has obscured that many objections are neither technically valid nor unique to the EFA. Compared with cost-effectiveness thresholds, only two objections apply uniquely to the EFA and concern intended key properties: (1) no external thresholds are needed and (2) the EFA is sensitive to price changes of comparators. Combining these policies and developing them further are under-utilized research areas. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/13669 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Lizenz gemäss Verlagsvertrag |
| Departement: | Gesundheit |
| Enthalten in den Sammlungen: | Publikationen Gesundheit |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Sandmann, F. G., Mostardt, S., Lhachimi, S. K., & Gerber-Grote, A. (2018). The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds? Expert Review of Pharmacoeconomics & Outcomes Research, 18(5), 475–486. https://doi.org/10.1080/14737167.2018.1497976
Sandmann, F.G. et al. (2018) ‘The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds?’, Expert Review of Pharmacoeconomics & Outcomes Research, 18(5), pp. 475–486. Available at: https://doi.org/10.1080/14737167.2018.1497976.
F. G. Sandmann, S. Mostardt, S. K. Lhachimi, and A. Gerber-Grote, “The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds?,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 18, no. 5, pp. 475–486, 2018, doi: 10.1080/14737167.2018.1497976.
SANDMANN, Frank G., Sarah MOSTARDT, Stefan K. LHACHIMI und Andreas GERBER-GROTE, 2018. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds? Expert Review of Pharmacoeconomics & Outcomes Research. 2018. Bd. 18, Nr. 5, S. 475–486. DOI 10.1080/14737167.2018.1497976
Sandmann, Frank G., Sarah Mostardt, Stefan K. Lhachimi, and Andreas Gerber-Grote. 2018. “The Efficiency-Frontier Approach for Health Economic Evaluation versus Cost-Effectiveness Thresholds and Internal Reference Pricing : Combining the Best of Both Worlds?” Expert Review of Pharmacoeconomics & Outcomes Research 18 (5): 475–86. https://doi.org/10.1080/14737167.2018.1497976.
Sandmann, Frank G., et al. “The Efficiency-Frontier Approach for Health Economic Evaluation versus Cost-Effectiveness Thresholds and Internal Reference Pricing : Combining the Best of Both Worlds?” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 18, no. 5, 2018, pp. 475–86, https://doi.org/10.1080/14737167.2018.1497976.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.